AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 11 min read$GRCE

Opaleye Management Inc. purchased $16K of GRCE (indirect holdings)

Opaleye Management Inc. purchased 7,849 indirectly-held shares of Grace Therapeutics, Inc. (GRCE) at $2.09 on 2026-09-29.

Original reporting
SEC EDGAR · Opaleye Management Inc.
Published Oct 1, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GRCE
Neutral
high confidence
Mentioned
$GRCE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GRCENeutralLow
01

Why it matters

The disclosed purchase is modest and unlikely to move the stock significantly.

02

Market read

A routine insider purchase with limited trading relevance.

03

What to watch

Potential future stake increase or upcoming corporate actions not disclosed.

Relevance 3/10Novelty 3/10Timing: today

Background

SEC Form 4 filings provide primary disclosure of insider transactions.

Company-level read

Ticker impact

$GRCENeutralHigh confidence
Context

Form 4 shows Opaleye Management purchased 7,849 shares of Grace Therapeutics at $2.09, raising its holding to 2,798,167 shares.

Expected impact

likely slight upward pressure as the market prices in the insider buy.

Evidence & confidence

The transaction size (~$16K) is trivial relative to market cap, so any price move will be minimal.

Market effects

Sector

Minimal effect on the biotech sector; insider activity is routine.

Regional

No discernible regional impact.

Global

Limited to investors tracking Grace Therapeutics.

Counterpoint

What could challenge this read

The purchase could be a strategic stake build, but the small size suggests no material intent.

Key entities

  • Company
    Grace Therapeutics, Inc.

    Biotech firm whose shares were purchased.

  • Investor
    Opaleye Management Inc.

    Entity that bought the shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GRCE insider trading history →

Related articles

AUG 13
$GRCEMed

Grace Therapeutics Announces First Quarter 2027 Financial Results

Grace Therapeutics, Inc. (GRCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99. 1 Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update Princeton, NJ, August 13, 2026 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104

SEC EDGAR 8-K6 min
JUN 18
$GRCEMed

Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results

Grace Therapeutics, Inc. (GRCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20076145_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Pr

SEC EDGAR 8-K4 min
OCT 7
$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $2.2M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 103,684 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $20.92 ($20.80–$21.09, $2.17M total) across 3 trades over 2026-10-02 to 2026-10-06. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Zolezzi William (10% owner), Divisadero Street Partners, L.P. (10% owner) and Divisadero Street Capital, LLC (10% owner).

SEC EDGAR1 min